Serveur Académique Lausannois SERVAL serval.unil.ch

Author Manuscript

Faculty of Biology and Medicine Publication

This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal pagination.

Published in final edited form as:

Title: Mortality of patients with COPD participating in chronic disease

management programmes: a happy end?

Authors: Peytremann-Bridevaux I, Taffe P, Burnand B, Bridevaux PO,

Puhan MA

Journal: Thorax

Year: 2014 Sep

Issue: 69

Volume: 9

Pages: 865-6

DOI: 10.1136/thoraxjnl-2013-204983

In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article.





Mortality of COPD patients participating in chronic disease management programmes: A happy end?

Peytremann-Bridevaux I¹, Taffe P¹, Burnand B¹, Bridevaux PO², Puhan MA³

Corresponding author:

Professor Isabelle Peytremann-Bridevaux Institute of Social and Preventive Medicine 10 route de la Corniche 1010 Lausanne Switzerland

Tel: #41 21 314 72 84

Fax: #4121

Email: Isabelle.Peytremann-Bridevaux@chuv.ch

Key words: COPD; systematic review; meta-analysis; mortality; chronic disease management

Word count: 575

¹ Institute of Social and Preventive Medicine, Healthcare Evaluation Unit, Lausanne University Hospital, Lausanne, Switzerland

² Centre Hospitalier du Valais Romand, Sion, Switzerland, and Geneva University Hospital, Division of Pulmonary Medicine, Geneva, Switzerland

³ Institute of Social and Preventive Medicine, University of Zurich, Zurich, Switzerland

ABSTRACT

Background: Concerns about increased mortality could question the role of COPD chronic disease management (CDM) programmes. We aimed at extending a recent Cochrane review to assess the effects of CDM on mortality in COPD patients.

Methods: Mortality data was available for 25 out of 29 trials identified in a COPD integrated care systematic review. Meta-analysis using random-effects models was performed, followed by subgroup analyses according to study length (3-12 months vs >12 months), main intervention component (exercise, self-management, structured follow-up), and use of an action plan.

Results: The meta-analysis showed no impact of CDM on mortality (pooled OR: 1.00, 95% CI 0.79-1.28).

Conclusions: These results do not suggest that CDM programmes expose patients with COPD to excessive mortality risk.

For more than two decades, chronic disease management (CDM) initiatives have been developed and implemented in many countries. CDM aims at reorganizing healthcare systems and medical treatment to address the increasing burden of chronic diseases and provide solutions to organizational, medical and economical problems. A recent Cochrane systematic review showed that in COPD patients, CDM significantly improved health-related quality of life as well as exercise tolerance (6-minutes walking test-MWT), and decreased the risk of hospitalization.[1] While updating non-Cochrane systematic reviews published in the mid-2000s and conducting a methodologically sound and rigorous Cochrane systematic review, Kruis et al confirmed previous trends in outcomes, indeed. Unfortunately, analyses of secondary outcomes, such as mortality, were not performed comprehensively enough from our perspective. In fact, out of 26 studies included in the review and three studies awaiting assessment,[2-4] only data from the five randomised controlled trials (RCTs) explicitly reporting mortality as an outcome were considered in the mortality meta-analysis. Mortality results are of crucial importance for those interested in CDM development and implementation in the field, particularly since Fan's publication in 2012.[3] In the latter study in fact, health benefits from such a program were counterbalanced by an unexpected and still unexplained significantly higher mortality in COPD patients participating in a comprehensive care program.

The aim of our targeted analyses was to assess mortality of COPD patients participating in CDM programmes using data from studies included in Kruis' recent Cochrane review.[1] Because all-cause mortality is an indisputable outcome, even if not a targeted study event, we considered all 29 RCTs described in Kruis' review: 26 RCTs meeting Kruis' operational definition of CDM (\geq 2 different types of healthcare professionals actively involved in patients care, \geq 2 intervention components, \geq 3 months duration) and included in the analyses, as well three studies identified as "awaiting assessment". [1] We reviewed the three latter studies and considered them to meet inclusion and exclusion criteria of the systematic review; one of the three was the Fan's

RCT.[3] Mortality data was available for 25 of the 29 eligible studies described in Kruis' review.

Baseline number of patients included in both CDM and control groups, number of deaths in each

group during studies' periods as well as studies' length, main intervention component and use of

action plan, were extracted. We conducted a random-effects meta-analysis, followed by subgroup

analyses according to study length (3-12 months vs >12 months), main intervention component

(exercise, self-management, structured follow-up) and specific use of an action plan in the

intervention.

Our enriched meta-analysis showed no impact of CDM on overall mortality (25 studies;

pooled odd ratio (OR): 1.00, 95%CI [0.79-1.28]; Figure). There was little evidence for

heterogeneity (I² 19%) and only discrete asymmetry as assessed by a funnel plot. All subgroup

analyses showed non-significant pooled odds ratios. As event rates were low, we also computed

the unweighted estimate of the pooled OR after adding 0.5 to observed frequencies of all studies,

as suggested by Bhaumik et al. [5] This methodology allows the inclusion of zero total events and

has been shown to perform better than the traditional DerSimonian and Laird approach in those

situations. Results were however similar to the standard ones (pooled OR=1.07 95%CI [0.58-

1.84], between-study variance Tau²=0.4). Varying the between-study variance (0.08≤Tau²≤0.6)

did not alter the results, thereby illustrating their robustness.

Results of this enriched meta-analysis do not suggest that complex interventions such

as CDM expose patients with COPD to excessive mortality risk, as feared by a recent RCT [3].

ACKNOWLEDGMENTS: None

COMPETING INTERESTS: None of the authors has any conflict of interest to declare

4

FUNDING: Prof. I. Peytremann-Bridevaux is supported by a grant from the Swiss NationalScience Foundation [PROSPER N° 32333B-123817 and N° 32333B-139789] and by the Swiss School of Public Health+ [Assistant Professorship grant].

REFERENCE LIST

- 1 Kruis AL, Smidt N, Assendelft WJJ, et al. Integrated disease management interventions for patients with chronic obstructive pulmonary diseases. *Cochrane Database Syst Rev* 2013 Oct 10;10:CD009437.
- 2 Baumann HJ, Kluge S, Rummel K, et al. Low intensity, long-term outpatient rehabilitation in COPD: a randomised controlled trial. *Resp Res* 2012;13:86.
- 3 Fan VS, Gaziano JM, Lew R, et al. A comprehensive care management program to prevent chronic obstructive pulmonary disease hospitalizations: a randomized, controlled trial. *Ann Intern Med* 2012;156:673–83.
- Zwar NA, Hermiz O, Comino E, et al. Care of patients with a diagnosis of chronic obstructive pulmonary disease: a cluster randomised controlled trial. *Med J Austr* 2012;197:394–8.
- 5 Bhaumil DK, Amatya A, Normand SL T, et al. Meta-analysis of rare binary adverse event data. *JASA* 2012;555-67.

Figure: Overall mortality forest-plot

	Integrated		Usual C			Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
Bauman	0	50	0	50		Not estimable	
Bendstrup	1	20	0	22	0.3%	3.46 [0.13, 89.95]	-
Bourbeau	5	96	9	95	6.5%	0.53 [0.17, 1.63]	
Boxal	1	30	2	30	1.5%	0.48 [0.04, 5.63]	
Dehda	0	15	0	18		Not estimable	
Engstrom	2	28	1	27	0.7%	2.00 [0.17, 23.44]	-
Fan	28	209	10	217	6.5%	3.20 [1.51, 6.77]	
Farrero	23	60	21	62	9.7%	1.21 [0.58, 2.54]	- - -
Fernandez	2	30	2	19	1.7%	0.61 [0.08, 4.72]	
Gottlieb	1	35	0	26	0.4%	2.30 [0.09, 58.86]	
Guell 2000	1	30	2	30	1.5%	0.48 [0.04, 5.63]	
Guell 2006	0	18	0	17		Not estimable	
Koff	0	20	0	20		Not estimable	
Littlejohns	3	73	9	79	6.3%	0.33 [0.09, 1.28]	
Mendes	0	88	0	29		Not estimable	
Rea	2	83	4	52	3.7%	0.30 [0.05, 1.68]	
Rice	36	372	48	371	33.1%	0.72 [0.46, 1.14]	-= †
Smith	8	48	7	48	4.4%	1.17 [0.39, 3.53]	
Sridhar	6	61	12	61	8.3%	0.45 [0.16, 1.28]	
Strijbos	2	35	0	15	0.5%	2.31 [0.10, 51.12]	
Theander	1	15	0	15	0.3%	3.21 [0.12, 85.20]	
Trappenburg	2	111	2	122	1.4%	1.10 [0.15, 7.95]	
Van Wetering	7	102	5	97	3.6%	1.36 [0.42, 4.43]	
Wood-Baker	5	67	4	72	2.7%	1.37 [0.35, 5.34]	
Zwar	14	234	9	217	6.7%	1.47 [0.62, 3.47]	+
Total (95% CI)		1930		1811	100.0%	1.00 [0.79, 1.28]	\
Total events	150		147				
Heterogeneity: Chi ² = 23.56, df = 19 (P = 0.21); l ² = 19%							
Test for overall effect: Z = 0.02 (P = 0.98) 0.01 0.1 1 10 100 Favours [experimental] Favours [control]							